Innovative Microbiome Therapies MaaT Pharma specializes in developing microbiome-driven immunomodulators for oncology and hematology, positioning it as a pioneer in a rapidly evolving sector that offers potential partnerships, licensing, and co-development opportunities with biotech and pharmaceutical companies focused on immune therapies.

Strong Clinical Progress With recent final results from phase 3 trials and presentation at major conferences such as ASH and EBMT, MaaT Pharma demonstrates robust clinical advancement and validation of its therapies, making it a compelling partner for investors and collaborators looking to accelerate innovative treatments to market.

Funding and Recognition Having secured €3.5 million from the European Investment Bank and received the 'Innovative Company' label from Bpifrance, MaaT Pharma exhibits strong backing, suggesting financial stability and potential for further investment engagement and strategic collaborations within the biotech ecosystem.

Market Focus on Oncology and Hematology Targeting cancer and graft-versus-host disease, MaaT Pharma’s focus on immune modulation in specialized markets presents opportunities for sales expansion in healthcare institutions, clinical research organizations, and pharmaceutical companies seeking advanced supportive treatments for cancer patient care.

Partnership and Collaboration Potential With an active presence in key industry events and a leadership team driving innovative research, MaaT Pharma is well-positioned for forming strategic alliances, licensing agreements, and joint ventures with organizations aiming to enhance immune therapies and expand market reach in biotech and healthcare sectors.